VIDEO: Pegcetacoplan reduces number of scotomatous points at 36 months

ByDilsher Dhoot, MD

ByEamon N. Dreisbach

ByDavid W. Mullin

Fact checked byChristine Klimanskis, ELS

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Dilsher S. Dhoot, MD, discusses the functional benefits of pegcetacoplan in patients with geographic atrophy.

“I was honored to present first-time data here demonstrating that pegcetacoplan met, for the first time of any GA drug, a prespecified visual functional endpoint,” he said. “That endpoint is the number of scotomatous points at month 36, and we saw a reduction that was statistically significant in the number of [new] scotomatous points in patients treated with pegcetacoplan [relative to sham].”

Editor’s note: This video caption was updated June 10, 2024, to add more specific information on the study results.

Published by:

Sources/Disclosures

Collapse

Source:

Dhoot DS. Analysis of functional parameters in pegcetacoplan treated eyes. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Disclosures: Dhoot reports consulting for Apellis.

Clinical Trials at the Summit meeting

Read more

VIDEO: Pegcetacoplan reduces number of scotomatous points at 36 months

Related Content